Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs BACI-RX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
FDA-approved: Treatment of superficial skin infections caused by susceptible organisms,Off-label: Ophthalmic infections (conjunctivitis, blepharitis), nasal carriage of Staphylococcus aureus
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 m L/min.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Bacitracin is not systemically absorbed after topical administration; no significant hepatic metabolism. Systemic absorption can occur with large topical doses or use on denuded skin, and it is excreted primarily unchanged by the kidneys.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Low protein binding; 0–11% bound, primarily to albumin.
Approximately 10-20% bound to serum proteins (albumin).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
0.25-0.4 L/kg. Low Vd indicates distribution primarily to extracellular fluid; minimal tissue penetration except renal cortex.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Intramuscular: ~100% (rapid and complete); oral: negligible (<1%) due to poor absorption; topical: variable, minimal systemic absorption (<5% with intact skin).
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No adjustment required; bacitracin is not significantly renally eliminated.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
No adjustment required; bacitracin is not hepatically metabolized.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Weight-based dosing as per standard protocol: 1-2 units/kg intramuscularly every 2-4 hours; adjust based on factor levels.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Use standard dosing with caution for renal function; assess GFR and adjust if impaired.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
No FDA black box warning.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Nephrotoxicity with systemic absorption; avoid use on large surface areas or deep wounds; hypersensitivity reactions; potential for superinfection; not for ophthalmic use unless specifically formulated.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Hypersensitivity to bacitracin or any component of the formulation; severe renal impairment (if systemic absorption is possible).
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
No known food interactions with topical bacitracin.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Unknown if excreted in human milk; M/P ratio not available. Caution is advised; consider temporary discontinuation of breastfeeding or drug based on importance to mother.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
No dose adjustment required due to pregnancy-related pharmacokinetic changes; dose based on indication and renal function.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
BACI-RX (bacitracin) is a topical antibiotic effective against gram-positive organisms. Avoid systemic use due to nephrotoxicity. Apply thin layer; hypersensitivity reactions possible. Not for ophthalmic use unless specified. Monitor for superinfection with prolonged use.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
Apply a thin layer to affected area as directed.,Wash hands before and after application unless treating hands.,Do not use on large areas of skin or deep puncture wounds.,Stop use and consult provider if rash or irritation develops.,Do not use in eyes or mouth unless specifically prescribed.,Store at room temperature away from moisture and heat.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs BACI-RX, answered by our medical review team.
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. BACI-RX is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and BACI-RX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. The standard adult dose of BACI-RX is: 1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and BACI-RX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. BACI-RX is classified as Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.